The Crohn’s Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Crohn’s Disease: An Overview
As per Crohn’s & Colitis Foundation, Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus. Additionally, ulcerative colitis, an IBD that causes long-lasting inflammation and ulcers (sores) in your digestive tract, is limited to the colon, also called the large intestine.
Crohn’s Disease is characterized by skip intestinal lesions (that is, areas of inflammation interposed between normal-appearing mucosa) anywhere in the GI tract. It involves chronic, relapsing transmural inflammation that can lead to chronic abdominal pain, diarrhea, obstruction, and/or perianal lesions.
Crohn’s Disease Market Key Facts
-
According to a study by Adcock et al., (2016), in the UK, it is estimated that at least 115,000 people have Crohn’s disease.
-
Crohn’s Disease can occur at any age and is more prevalent among adolescents and young adults between the ages of 15 and 35.
-
According to a study conducted by Galeone et al., (2019), in Italy, the area of Casteltermini in Sicily had one of the highest prevalence ratios of CD (322/100,000) reported worldwide.
-
Studies have demonstrated that the incidence rates and prevalence rates for Crohn’s disease have increased since the mid-1970s. Its prevalence has continually increased over the past 50 years, with the highest incidence being reported in northern Europe, the United Kingdom, and North America.
Extensive research and development activities of pharmaceutical companies for developing therapies for Crohn’s disease, rising prevalent population, changing lifestyles, rise in smoking will fuel the growth of the Crohn’s Disease market.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Crohn’s Disease market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Crohn’s Disease market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Crohn’s Disease Epidemiology
The epidemiology section covers insights about the historical and current Crohn’s Disease patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Crohn’s Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Crohn’s Disease market or expected to get launched in the market during the study period. The analysis covers Crohn’s Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Crohn’s Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/crohns-disease-cd-market
Crohn’s Disease Therapeutics Analysis
The dynamics of the Crohn’s Disease market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.
Several companies across the globe are working toward the development of new treatment therapies for Crohn’s disease rigorously. The launch of the pipeline therapies is expected to transform the treatment dynamics in the coming years.
Some of the key companies in the Crohn’s Disease Market Includes:
-
UCB
-
Abbvie
-
Genetech
-
Gilead Sciences
-
Celgene Corporation
-
Millennium Pharmaceuticals
And many others
Crohn’s Disease Therapies covered in the report includes:
-
Filgotinib
-
Risankizumab
-
Etrolizumab
-
PDA-001
And many other
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/crohns-disease-cd-market
Table of Content
1. Key Insights
2. Executive Summary
3. Crohn’s Disease Competitive Intelligence Analysis
4. Crohn’s Disease Market Overview at a Glance
5. Crohn’s Disease Disease Background and Overview
6. Crohn’s Disease Patient Journey
7. Crohn’s Disease Epidemiology and Patient Population
8. Crohn’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Crohn’s Disease Unmet Needs
10. Key Endpoints of Crohn’s Disease Treatment
11. Crohn’s Disease Marketed Products
12. Crohn’s Disease Emerging Therapies
13. Crohn’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Crohn’s Disease Market Outlook (7 major markets)
16. Crohn’s Disease Access and Reimbursement Overview
17. KOL Views on the Crohn’s Disease Market.
18. Crohn’s Disease Market Drivers
19. Crohn’s Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/crohns-disease-cd-market
Other Trending Healthcare Reports By DelveInsight
Epstein Barr Virus (EBV) Market
DelveInsight’s “Epstein Barr virus (EBV) Market” report delivers an in-depth understanding of the Epstein Barr virus (EBV), historical and forecasted epidemiology as well as the Epstein Barr virus (EBV) market trends in 7MM. As per DelveInsight, the Epstein Barr virus (EBV) Market is expected to grow in the coming years owing to the active participation of key companies such as Atara Biotherapeutics, AlloVir, Tessa Therapeutics, Viracta Therapeutics, Seagen, RAPT Therapeutics, Merck, Eutilex, Atara Biotherapeutics, Labolife, and Others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/